{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Klasener K"],"funding":["Stiftelserna Wilhelm och Martina Lundgrens","Vetenskapsrådet","Swedish Cancer Foundation","Stiftelsen Apotekare Hedbergs Fond för Medicinsk Forskning","Roche Innovation Center Zurich","Barncancerfonden","Kungl. Vetenskaps- och Vitterhets-Samhället i Göteborg","IngaBritt och Arne Lundbergs Forskningsstiftelse","Åke Wiberg Stiftelse","Adlerbertska Research Foundation","Reumatikerförbundet","Deutsche Forschungsgemeinschaft","Stiftelsen Assar Gabrielssons Fond"],"pagination":["e70011"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11447455"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(10)"],"pubmed_abstract":["<h4>Objectives</h4>Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting monoclonal antibodies (mAbs), daratumumab and isatuximab, in impairing crucial cellular processes and survival pathways in pBL malignant cells.<h4>Methods</h4><i>In silico</i> analyses of patient samples, combined with <i>in vitro</i> experiments using the Ramos cell line, were conducted to assess the impact of daratumumab and isatuximab on cellular proliferation, apoptosis and the phosphoinositide 3-kinase (PI3K) pathway.<h4>R"],"journal":["Clinical & translational immunology"],"pubmed_title":["Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells."],"pmcid":["PMC11447455"],"funding_grant_id":["BGR23‐03","19 0464","FB21‐104","2018‐03128","PR2020‐0147","FB22‐70","PR2018‐0170"],"pubmed_authors":["Herrmann N","Boren J","Visentini M","Lundqvist C","Reth M","Camponeschi A","Aranburu A","Klasener K","Sundell T","Manna PT","Forsman H","Fogelstrand L","Martensson IL","Ljung Sass D","Jonsson CA","Sundqvist M","Mellgren K","Gjertsson I","Grimstad K","Ekwall O","Haversen L","McGrath S"],"additional_accession":[]},"is_claimable":false,"name":"Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.","description":"<h4>Objectives</h4>Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting monoclonal antibodies (mAbs), daratumumab and isatuximab, in impairing crucial cellular processes and survival pathways in pBL malignant cells.<h4>Methods</h4><i>In silico</i> analyses of patient samples, combined with <i>in vitro</i> experiments using the Ramos cell line, were conducted to assess the impact of daratumumab and isatuximab on cellular proliferation, apoptosis and the phosphoinositide 3-kinase (PI3K) pathway.<h4>R","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-14T05:21:06.946Z","creation":"2025-04-04T02:30:03.751Z"},"accession":"S-EPMC11447455","cross_references":{"pubmed":["39364393"],"doi":["10.1002/cti2.70011"]}}